Tactile Systems (TCMD) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
10 Mar, 2026Executive summary
Annual Meeting scheduled for May 6, 2026, to elect nine directors, ratify the auditor, approve executive compensation, and amend the Certificate of Incorporation regarding director removal.
Proxy materials are available online, with options for electronic or paper delivery to shareholders.
Board recommends voting FOR all proposals.
Voting matters and shareholder proposals
Proposals include: election of nine directors, ratification of Grant Thornton LLP as auditor for 2026, advisory approval of 2025 executive compensation, and amendment to allow director removal consistent with Delaware law.
Board recommends FOR all proposals.
Shareholders may submit proposals for the 2027 meeting by November 25, 2026.
Board of directors and corporate governance
Board consists of nine nominees, eight of whom are independent; all committees are fully independent.
Board leadership is separated between CEO and Chairman.
Annual election of all directors; no supermajority voting or poison pill.
Board and committees conduct annual evaluations, and stockholders can communicate directly with the Board.
Board diversity includes gender and racial/ethnic representation.
Latest events from Tactile Systems
- Q4 revenue up 10.2% year-over-year; 2025 guidance targets 8%-10% growth.TCMD
Q4 20249 Jul 2026 - Q3 revenue up 5%, gross margin expands, net income down, $30M buyback program announced.TCMD
Q3 20249 Jul 2026 - Growth in lymphedema and bronchiectasis markets accelerates with new products and tech investments.TCMD
The 44th Annual William Blair Growth Stock Conference9 Jul 2026 - Q2 revenue up 7%, net income $4.3M, guidance cut, but growth drivers and cash flow remain strong.TCMD
Q2 20248 Jul 2026 - Market leader in compression therapies, driving growth with innovation and expanded patient access.TCMD
46th Annual William Blair Growth Stock Conference2 Jun 2026 - Q1 2026 revenue up 23% to $75.3M, gross margin at 76.5%, and LymphaTech acquisition completed.TCMD
Q1 20267 May 2026 - Key votes include director elections, auditor ratification, and a say-on-pay advisory for 2025.TCMD
Proxy filing25 Mar 2026 - Proxy covers director elections, auditor ratification, compensation, and governance changes.TCMD
Proxy filing25 Mar 2026 - Double-digit revenue and margin growth in 2025, with 2026 guidance for continued expansion.TCMD
Q4 202517 Feb 2026